SEPN — Septerna, Inc. Common Stock

Septerna, Inc. Common Stock (SEPN) is a biotechnology company listed on NASDAQ. It is led by Jeffrey T. Finer M.D., Ph.D., based in 250 East Grand Avenue, South San Francisco, CA, United States, 94080, with about 130 employees. Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.

Latest reported SEPN revenue for 2025-09-30 was $21.5M. Net income was -$38.1M. Revenue was up 17963.0% from 2025-06-30 to 2025-09-30. SEPN currently screens at market cap $1.61B.

Use this SEPN page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the SEPN quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the SEPN SEC filings page. Lician reads the product cache first so this HTML stays unique to Septerna, Inc. Common Stock even when a live quote feed is slow.